Selected article for: "immune response and vaccine target"
Author: Watanabe, Yasunori; Allen, Joel D.; Wrapp, Daniel; McLellan, Jason S.; Crispin, Max
Title: Site-specific analysis of the SARS-CoV-2 glycan shield
  • Cord-id: 63j4qc7d
  • Document date: 2020_3_28
    • ID: 63j4qc7d
    Snippet: The emergence of the betacoronavirus, SARS-CoV-2 that causes COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, that mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in immune evasion and occluding immunogenic protein epitopes. Here, using a site-specific mass spectrometric approach, w
    Document: The emergence of the betacoronavirus, SARS-CoV-2 that causes COVID-19, represents a significant threat to global human health. Vaccine development is focused on the principal target of the humoral immune response, the spike (S) glycoprotein, that mediates cell entry and membrane fusion. SARS-CoV-2 S gene encodes 22 N-linked glycan sequons per protomer, which likely play a role in immune evasion and occluding immunogenic protein epitopes. Here, using a site-specific mass spectrometric approach, we reveal the glycan structures on a recombinant SARS-CoV-2 S immunogen. This analysis enables mapping of the glycan-processing states across the trimeric viral spike. We show how SARS-CoV-2 S glycans differ from typical host glycan processing, which may have implications in viral pathobiology and vaccine design.

    Search related documents:
    Co phrase search for related documents
    • acute respiratory syndrome and adaptive immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72
    • acute respiratory syndrome and additional purification: 1
    • acute respiratory syndrome and local protein: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and local protein structure: 1
    • acute respiratory syndrome and loop structure: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • acute respiratory syndrome and low mutation: 1, 2, 3, 4, 5, 6, 7, 8, 9
    • acute respiratory syndrome and low mutation rate: 1, 2
    • acute respiratory syndrome and low sars mutation rate: 1
    • adaptive immunity and low mutation: 1, 2, 3
    • adaptive immunity and low mutation rate: 1
    • adaptive immunity and low sars mutation rate: 1
    • local protein and low mutation: 1
    • local protein and low mutation rate: 1